2004

Structure of Shiga Toxin Type 2 (Stx2) from *Escherichia coli* O157:H7

Marie E. Fraser  
*University of Calgary*

Masao Fujinaga  
*University of Alberta*

Maia M. Cherney  
*University of Alberta*

Angela R. Melton-Celsa  
*Uniformed Services University of the Health Sciences*, angela.melton-celsa@usuhs.edu

Edda M. Twiddy  
*Uniformed Services University of the Health Sciences*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.unl.edu/usuhs

Part of the Medicine and Health Sciences Commons

Fraser, Marie E.; Fujinaga, Masao; Cherney, Maia M.; Melton-Celsa, Angela R.; Twiddy, Edda M.; O’Brien, Alison D.; and James, Michael N. G., "Structure of Shiga Toxin Type 2 (Stx2) from *Escherichia coli* O157:H7" (2004). *Uniformed Services University of the Health Sciences*. 109.  
https://digitalcommons.unl.edu/usuhs/109

This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Uniformed Services University of the Health Sciences by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Authors
Marie E. Fraser, Masao Fujinaga, Maia M. Cherney, Angela R. Melton-Celsa, Edda M. Twiddy, Alison D. O'Brien, and Michael N. G. James
Structure of Shiga Toxin Type 2 (Stx2) from *Escherichia coli* O157:H7*

Received for publication, February 22, 2004, and in revised form, April 7, 2004
Published, JBC Papers in Press, April 9, 2004, DOI 10.1074/jbc.M401939200

Marie E. Fraser‡, Masao Fujinaga‡, Maia M. Cherney§, Angela R. Melton-Celsa¶, Edda M. Twiddy‡, Alison D. O’Brien‡, and Michael N. G. James§

From the ‡Department of Biological Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada, the §Canadian Institutes for Health Research Group in Protein Structure and Function, Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada, and the ¶Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814

Several serotypes of *Escherichia coli* produce protein toxins closely related to Shiga toxin (Stx) from *Shigella dysenteriae* serotype 1. These Stx-producing *E. coli* cause outbreaks of hemorrhagic colitis and hemolytic uremic syndrome in humans, with the latter being more likely if the *E. coli* produce Stx2 than if they only produce Stx1. To investigate the differences among the Stxs, which are all AB5 toxins, the crystal structure of Stx2 from *E. coli* O157:H7 was determined at 1.8-Å resolution and compared with the known structure of Stx. Our major finding was that, in contrast to Stx, the active site of the A-subunit of Stx2 is accessible in the holotoxin, and a molecule of formic acid and a water molecule mimic the binding of the adenine base of the substrate. Further, the A-subunit adopts a different orientation with respect to the B-subunits in Stx2 than in Stx, due to interactions between the carboxyl termini of the B-subunits and neighboring regions of the A-subunit. Of the three types of receptor-binding sites in the B-pentamer, one has a different conformation in Stx2 than in Stx, and the carboxyl terminus of the A-subunit binds at another. Any of these structural differences might result in different mechanisms of action of the two toxins and the development of hemolytic uremic syndrome upon exposure to Stx2.

Several serotypes of *Escherichia coli* produce one or more protein toxins that are closely related to Stx from *Shigella dysenteriae* serotype 1 (1). Stx from *S. dysenteriae* was first identified by Kiyoshi Shiga for whom these toxins are named (2). Collectively these *E. coli* are known as Stx-producing *E. coli* (STEC). 1. *E. coli* O157:H7 is the STEC responsible for many outbreaks of hemorrhagic colitis or bloody diarrhea in the U.S., Canada, and Japan. In some patients the prodrome of hemorrhagic colitis may progress to the hemolytic uremic syndrome, which culminates in kidney failure. Two types of Stx may be produced by STEC, Stx1 and/or Stx2. The Stx types all have an AB5 structure, in which a single A-subunit is associated with five B-subunits. The A-subunit embodies the N-glycosidase catalytic activity; it acts by removing a specific adenine base from the 28 S rRNA of the 60 S ribosomal subunit within infected cells. Because this adenine base is on a loop of rRNA that is important for elongation factor binding, the toxin is able to shut down protein synthesis in a targeted cell. The A-subunit of Stx1 is nearly identical to the A-subunit of Stx; it differs only by the change of a single serine residue at position 45 to a threonine (Table I). In contrast, the amino acid sequence identity between the A-subunits of Stx1 and Stx2 is only 55%. The B-pentamer of the Stxs contains the binding sites for glycolipids that are located on the surface of target cells, and thus mediates entry of the catalytic A-subunit into cells. Although the Stx1 group is homogeneous, the Stx2 group has a number of variants. Variants of Stx2 include Stx2e, Stx2d, Stx2d-activable, Stx2e, and Stx2f. Only the Stx2e variant of Stx2 has been found in the O157 serotypes. The Stx2 variants are distinguished by a difference in biological activity, immunological reactivity, or the receptor to which they bind. Stx1, Stx2, and the Stx2 variants bind preferentially to the glycosphingolipid globotriaosylceramide (Galα1–4Galβ1–4glucosyl ceramide, Glcβ3) with the exception of Stx2e, which binds preferentially to globotetraosylceramide (Galα2–3Galα1–4Galβ1–4glucosyl ceramide). These different binding properties lead to the ability of the toxin to target different cells.

The molecular structure of the Stx1 B-pentamer alone was first determined using x-ray crystallography. This structure showed five B-subunits in a pentameric arrangement (3), similar to the arrangement of the B-subunits of the heat-labile enterotoxin (4). In heat-labile enterotoxin the five B-subunits surround a pore through which the carboxyl-terminal residues of the A-subunit traverse. When the structure of Stx was solved, the carboxyl-terminal tail of the A-subunit was found to be surrounded by its five B-subunits like heat-labile enterotoxin, whereas the remainder of the A-subunit lay on one side of the B-pentamer (5). The determinations of the structures of the Stx1 B-subunits and of their mutated forms, alone and in complex with sugars, have led to a better understanding of the binding properties of the B-pentamer (6–8) and have served as templates in the design of inhibitors to cell binding (9, 10).

The A-subunit of the Stxs can be proteolytically cleaved at a susceptible site (11), but the two portions, A1 (27.5 kDa) and A2 (4.5 kDa), remain covalently associated through a disulfide...
The sequence alignments were generated using ClustalW (39). For Stx, the sequence identifiers are CAA30741 and CAA30742 from Ref. 40; for Stx1 A, the sequence identifier is AAA98151 from Ref. 41; for Stx2, the sequence identifiers are CAA30744 and CAA30745 from Ref. 42.

The catalytic mechanism of ricin has been investigated in detail: the adenine base (13) and subsequently confirmed with genetic studies (summarized in Ref. 14). The catalytic mechanism of the B-subunits of Stx or Stx1 and Stx2 has been investigated extensively (15). The tissue damage may be due to these other effects of the toxins and could be mediated by residues of the holotoxin that are not involved in receptor binding.

We have determined the structure of Stx2 and compared it to that of Stx to contribute to the understanding of what distinguishes Stx1 and Stx2 from each other. The experimental procedures of the holotoxins can be used as templates upon which to model anti-infective compounds to treat the diseases caused by E. coli O157:H7 and other STECs. They can also be used to design chimeras that could be used to decipher the different mechanisms of action of the two protein toxins in animal models.

**EXPERIMENTAL PROCEDURES**

**Expression, Purification, and Crystallization of Stx2—Stx2 was produced in E. coli DH5α using the plPSH3 plasmid and purified by immunoaffinity chromatography as previously described (13).** The toxin eluted from the column with 0.1 M glycine, pH 7.8, and was dialyzed in 0.1 M MES (pH 6.0), 50 mM 3-(1-pyridino)-1-propanesulfonate (PPS), and 1% ethylene glycol then vitrified at 100 K in the reservoir solution. The reservoir solution contained 4 M sodium formate, 0.2 M NaCl, and 1% ethylene glycol. After a few days, crystals appeared as hexagonal crystals growing to a maximum size of 0.35 mm by 0.30 mm within 3 weeks.

**Statistics for the crystallographic data of Stx2**

| Space group | P6₁ |
|-------------|-----|
| Number of measurements | 187,198 |
| Number of unique reflections | 66,898 |
| Completeness (%) overall (1.86–1.80 Å) | 98.3% (99.1%) |
| Rmerge overall (1.86–1.80 Å) | 8.9 (2.8) |
| a Rmerge = ∑ₙ|Iᵢ|−|Iᵢ₀|/∑ₙ|Iᵢ₀| (2.5%) |

**Structure Determination and Analysis—The crystals of Stx2 diffract to better than 1.8 Å resolution.** For the data collection, one crystal was transferred to a solution containing 30% glycerol, 4 M sodium formate, 0.1 M MES (pH 7.5), and 1% ethylene glycol and then cryocooled in liquid nitrogen. The crystals were screened using the programs ALMN (19) and BRUTE (20). The structure solution was generated by the molecular replacement method using the programs AMoRe (19) and BRUTE (20). The structure solution was performed in two stages, finding first the orientation and position of the B-subunit and the Stx2 domain. The N-terminal residue of the Stx2 domain was predicted from the structure of Stx2 (Table I). The structure of Stx2 was determined to 1.8 Å resolution using molecular replacement and differenced maps calculated by the programs AMoRe (21) and BRUTE (22). The structure was refined to an R value of 0.18 at 1.8 Å resolution. The structure was solved by the molecular replacement method using the programs AMoRe (19) and BRUTE (20). The structure solution was performed in two stages, finding first the orientation and position of the B-subunit and the Stx2 domain. The N-terminal residue of the Stx2 domain was predicted from the structure of Stx2 (Table I). The structure of Stx2 was determined to 1.8 Å resolution using molecular replacement and differenced maps calculated by the programs AMoRe (21) and BRUTE (22). The structure was refined to an R value of 0.18 at 1.8 Å resolution.

**Table I**

**Sequence alignments of the A-subunits of Stx, Stx1, A2, ricin, and the B-subunits of Stx or Stx1 and Stx2**

| A-subunit | A2 Subunit | A1 Subunit | B-subunit |
|-----------|------------|------------|-----------|
| Stx A     | Stx1 A     | Stx2 A     | Stx2 B    |
| Stx1 A    | Stx1 A     | Stx2 A     | Stx2 B    |
| Ricin A   | Stx1 A     | Stx2 A     | Stx2 B    |

| A-subunit | A2 Subunit | A1 Subunit | B-subunit |
|-----------|------------|------------|-----------|
| Stx A     | Stx1 A     | Stx2 A     | Stx2 B    |
| Stx1 A    | Stx1 A     | Stx2 A     | Stx2 B    |
| Ricin A   | Stx1 A     | Stx2 A     | Stx2 B    |

**Table II**

**Statistics for the crystallographic data of Stx2**

| Space group | P6₁ |
|-------------|-----|
| Number of measurements | 187,198 |
| Number of unique reflections | 66,898 |
| Completeness (%) overall (1.86–1.80 Å) | 98.3% (99.1%) |
| Rmerge overall (1.86–1.80 Å) | 8.9 (2.8) |
| a Rmerge = ∑ₙ|Iᵢ|−|Iᵢ₀|/∑ₙ|Iᵢ₀| (2.5%) |

**Structure Determination and Analysis—The crystals of Stx2 diffract to better than 1.8 Å resolution.** For the data collection, one crystal was transferred to a solution containing 30% glycerol, 4 M sodium formate, 0.1 M MES (pH 7.5), and 1% ethylene glycol and then cryocooled in liquid nitrogen. The crystals were screened using the programs AMoRe (19) and BRUTE (20). The structure solution was performed in two stages, finding first the orientation and position of the B-subunit and the Stx2 domain. The N-terminal residue of the Stx2 domain was predicted from the structure of Stx2 (Table I). The structure of Stx2 was determined to 1.8 Å resolution using molecular replacement and differenced maps calculated by the programs AMoRe (21) and BRUTE (22). The structure was refined to an R value of 0.18 at 1.8 Å resolution. The structure was solved by the molecular replacement method using the programs AMoRe (19) and BRUTE (20). The structure solution was performed in two stages, finding first the orientation and position of the B-subunit and the Stx2 domain. The N-terminal residue of the Stx2 domain was predicted from the structure of Stx2 (Table I). The structure of Stx2 was determined to 1.8 Å resolution using molecular replacement and differenced maps calculated by the programs AMoRe (21) and BRUTE (22). The structure was refined to an R value of 0.18 at 1.8 Å resolution.

**EXPERIMENTAL PROCEDURES**

**Expression, Purification, and Crystallization of Stx2—Stx2 was produced in E. coli DH5α using the plPSH3 plasmid and purified by immunoaffinity chromatography as previously described (13).** The toxin eluted from the column with 0.1 M glycine, pH 7.8, and was dialyzed in 0.1 M MES (pH 6.0), 50 mM 3-(1-pyridino)-1-propanesulfonate (PPS), and 1% ethylene glycol. After a few days, crystals appeared as hexagonal crystals growing to a maximum size of 0.35 mm by 0.30 mm within 3 weeks.

**Statistics for the crystallographic data of Stx2**

| Space group | P6₁ |
|-------------|-----|
| Number of measurements | 187,198 |
| Number of unique reflections | 66,898 |
| Completeness (%) overall (1.86–1.80 Å) | 98.3% (99.1%) |
| Rmerge overall (1.86–1.80 Å) | 8.9 (2.8) |
| a Rmerge = ∑ₙ|Iᵢ|−|Iᵢ₀|/∑ₙ|Iᵢ₀| (2.5%) |

**Structure Determination and Analysis—The crystals of Stx2 diffract to better than 1.8 Å resolution.** For the data collection, one crystal was transferred to a solution containing 30% glycerol, 4 M sodium formate, 0.1 M MES (pH 7.5), and 1% ethylene glycol and then cryocooled in liquid nitrogen. The crystals were screened using the programs AMoRe (19) and BRUTE (20). The structure solution was performed in two stages, finding first the orientation and position of the B-subunit and the Stx2 domain. The N-terminal residue of the Stx2 domain was predicted from the structure of Stx2 (Table I). The structure of Stx2 was determined to 1.8 Å resolution using molecular replacement and differenced maps calculated by the programs AMoRe (21) and BRUTE (22). The structure was refined to an R value of 0.18 at 1.8 Å resolution.
of the B-pentamer in the asymmetric unit and, subsequently, the orientation and location of the A-subunit. The search model for the B-pentamer was the structure of a mutant form of Stx2e (8), identified as 2BOS in the Protein Data Bank (21). The rotation function for the B-pentamer gave five peaks as expected, and the translation function clearly showed that the space group was P61. The search model for the

| Table III |
|---|---|
| **Toxin type** | **Stx2** | **Stx** |
| Resolution limit | 1.77 Å | 2.5 Å |
| Cell dimensions | 143.96 Å, a = 90°, b = 147.18 Å, c = 82.85 Å | 133.00 Å, a = 90°, b = 143.96 Å, c = 137.20 Å |
| Number of data for refinement | 66,890 | 53,527 |
| Completeness | 97.6% | 93.9% |
| R-factor (number of data) | 15.1% (63,514) | 19.9% (50,780) |
| R free (number of data) | 18.4% (3,376) | 25.7% (2,747) |
| Number of protein atoms | 4,981 | 9,687 |
| Number of water molecules | 511 | 46 |
| Number of atoms in ions or ligands | 125 | 0 |
| r.m.s. deviations from ideal geometry | 0.017 Å | 0.016 Å |
| Bond angles (°) | 2.0 | 1.9 |
| Ramachandran plot | 522 (92.6%) | 934 (85.8%) |
| Number in most favored regions | 42 (7.4%) | 147 (13.5%) |
| Number in additional allowed regions | 0 | 6 (0.6%) |
| Number in generously allowed regions | 0 | 1 (0.1%) |
| Number in disallowed regions | 0 | 1 (0.1%) |

**Fig. 1. Electron density for Stx2.** The electron density from the 2Fo − Fc map is contoured at 1σ near residues forming the active site. The molecular model is drawn as sticks, with water molecules depicted as filled circles. This figure was drawn with the programs BOBSCRIPT and MOLSCRIPT (35, 36).

**Fig. 2. Ribbon diagram of Stx2.** The A-subunit is red, whereas the B-subunits are orange (chain B), cyan (chain C), green (chain D), yellow (chain E), and blue (chain F). The active site in the A-subunit is marked by the magenta letter A. The side chains of the cysteine residues that link A1 and A2 are depicted in yellow. The sites equivalent to the Gb3-binding sites on the B-pentamer of Stx1 are shown by magenta numbers that distinguish the type of binding site (6). This figure and Figs. 6 and 7 were drawn with the programs MOLSCRIPT and RASTER3D (35, 37).
A-subunit was the A-subunit of Stx (5), using chain A of the structure identified as 1DM0 in the Protein Data Bank (21). The model was improved by cycles of maximum likelihood refinement using the Crystallography and NMR System (22) and model building using the molecular graphics programs XFIT (23) and TOM/FRODO (24). The quality of the model was judged with information from the programs PROCHECK (25) and WHATCHECK (26), and the final unit cell dimensions were those suggested by WHATCHECK.

The structure of Stx had been determined at lower resolution (2.5 Å) (27) than that of Stx2 (1.77 Å), so we hypothesized that the model for Stx could be improved by using information from the structure of Stx2. As well, Stx had been refined prior to the use of the maximum likelihood target in refinement (28). For these reasons, the Stx model was refined for several additional cycles using the original data set (5). The final refined structures of Stx and Stx2 were analyzed and compared using programs from the CCP4 package (19) as well as the molecular graphics programs O (29) and Swiss PDB Viewer (30). The atomic coordinates and the structure factors for both Stx2 and Stx have been deposited in the Protein Data Bank (21), where they have been assigned the identifiers 1R4P for Stx2 and 1R4Q for Stx.

---

**RESULTS**

**Stx2**—Table II presents the crystallographic details for Stx2, and Table III presents the statistics from the refinement. This is a well determined structure, as demonstrated by the low values of the R-factors and the excellent geometry of the refined model. The catalytic site of the A-subunit of Stx2 is accessible in the crystal structure, and Fig. 1 shows that it contains electron density. Three water molecules could be modeled into this electron density, and their positions and temperature factors were refined. The distances from these water molecules to atoms of the protein were reasonable hydrogen bonding distances, but the three were too close to each other for hydrogen-bonding (2.0, 2.1, and 2.2 Å). Instead, for the final model, a molecule of formic acid (used to crystallize the protein) has been modeled in two alternate conformations to account for the electron density. The crystal structure of Stx2 shows that most of the A-subunit is located on one side of the B-pentamer, but residues of A2 traverse the pore of the B-pentamer and form a short helix on the cell surface binding side (see Fig. 2). In the pore, residues of the A2 portion of Stx2 begin in an α-helical conformation (residues Ser-A278 to Leu-A285), changing to an extended conformation from Asn-A286 to Ser-A289. (The nomenclature indicates the amino acid residue followed by the chain letter and the position of the amino acid residue in that chain.) Ser-A289 initiates the final helix near the carboxyl terminus of the A-subunit. This terminal helix projects out of the B-pentamer pore at an angle of about 30° to the base of the B-pentamer and packs alongside two of the B-subunits. The final two residues of the A-subunit (Gly-A296 and Lys-A297) are not part of the helix, but they are well ordered in the structure.

**Stx**—We next took the information from the structure of Stx2 and refined further the structure of Stx. The new refinement improved the electron density in some regions, notably residues 43–46 and 184–188 of the A-subunit. Two and three additional residues could be fit at the carboxyl termini of A1 and A2, respectively, but the remaining carboxyl-terminal residues are disordered in the crystal structure. Data for the newly refined model for Stx are included in Table II.

**DISCUSSION**

**Active Site of Stx2**—The active site of the A subunit is accessible in Stx2 in contrast to the active site of the A subunit in Stx. In the crystal structure of Stx2, a molecule of formic acid and a water molecule bound in the active site mimic the binding of adenine (Fig. 3). The water molecule interacting with Arg-A170 closely approximates the position of N3 of adenine when bound to ricin (31). The oxygen atoms of formic acid occupy roughly the positions of N1 and N6 or N1 and N7 of the adenine in the two alternate orientations of the molecule of formic acid, and the carbon atom approximates the position of C6 of adenine. The tyrosine residue (residue A77) that forms hydrogen bonding interactions, and the interatomic distances are noted. A, configuration of the two alternate conformations of formic acid and a water molecule in the active site of Stx2. B, adenine bound to the A chain of ricin (31). This figure was drawn using the program LIGPLOT (38).

**Fig. 3.** Active site of Stx2 (A) and ricin (B). Dashed lines represent hydrogen bonding interactions, and the interatomic distances are noted. A, configuration of the two alternate conformations of formic acid and a water molecule in the active site of Stx2. B, adenine bound to the A chain of ricin (31). This figure was drawn using the program LIGPLOT (38).

---

**Fig. 4.** Ca trace of Stx2 superposed on that of Stx. Stx2 is shown in solid lines, whereas Stx is shown in dashed lines in this stereoview. The superposition was based solely on structurally equivalent residues of the B-pentamers. This figure and Fig. 5 were drawn with the program MOLSCRIPT (35).
and Stx2, as well as in the structures of ricin alone and in ricin when complexed with adenine. The different conformations of the tyrosine residue in these active sites indicate that this tyrosine side chain could adopt different conformations during a catalytic cycle. The role of the tyrosine residue in catalysis is most likely to bind the substrate by stacking with the adenine
However, in the structure of Stx, this tyrosine residue forms a hydrogen bond through its hydroxyl group with the carbonyl oxygen atom of Pro-A258, one of the residues of A2. It is this stretch of A2 that lies across the active site of Stx, as shown in Fig. 4.

Superpositions of Stx2 and Stx — The orientation of the A-subunit with respect to the B-pentamer differs in the two holotoxins Stx2 and Stx. Fig. 5 shows the superposition of the two holotoxins using only residues of the B-pentamers to align the structures, which superpose with an r.m.s. deviation of 1.3 Å for the 340 Ca atoms. The A-subunits superpose with an r.m.s. deviation of 0.84 Å for 246 Ca atoms. The sequences of the A-subunits are most different in the region of the cleavage loop and in the stretch of polypeptide following the second cysteine residue. The B-subunits of Stx2 are two residues longer at the carboxyl terminus than the B-subunits of Stx; in both toxins, the carboxyl-terminal residues of the B-subunits interact with the A-subunit. These different specific interactions may be responsible for the different orientations of the A-subunits with respect to their B-pentamers in the holotoxins.

Comparison of the Receptor-binding Sites — Three distinct receptor-binding sites have been identified on the B-pentamer of Stxs (6). Fig. 2 shows the locations of the equivalent sites on Stx2.

Carbohydrate Binding Site 1 — Receptor binding site 1 is located in a groove formed by two B-subunits where they interact to create the seven-stranded β-sheet. A molecule of 3-(1-pyridino)-1-propanesulfonate (PPS) is bound to Stx2 in four of the five potential type 1 binding sites. Fig. 6A demonstrates how the phenyl ring of PPS stacks against the indole ring of Trp-C29, mimicking the binding of the second galactose ring of the carbohydrate. The sulfonate group of each molecule of PPS also interacts with the B-pentamer, primarily via a water molecule that forms a link to Glu-15 of the B-subunit and to the side chain of Glu-64 of the neighboring B-subunit. This interaction could be exploited in the design of anti-infectives that would bind to site 1.

Carbohydrate Binding Site 2 — The conformation of Stx2 at the type 2 binding site differs from that of Stx, and the differences in both the sequences and the conformations are likely to lead to the different binding affinities for Gb3. The first residue of the B-subunit of Stx2 is alanine, which aligns with Pro-2 of the B-subunit of Stx. The NH$_3$ group of Ala-1 forms a hydrogen bond to the carbonyl oxygen atom of Ser-B53, leading to a different conformation in the loop to which the carbohydrate binds (Fig. 6B). The disulfide bond between cysteine residues B3 and B56 of Stx2 adopts a conformation different from that of the disulfide link between residues B4 and B57 of Stx1. For Gb$_3$ to bind to Stx2 in the same way that the Gb$_3$ analogue binds to the B-pentamer of Stx1, there would have to be a change in the conformation of this disulfide-bridged loop, otherwise the carbohydrate would clash with Ser-B54.

Carbohydrate Binding Site 3 — The type 3 binding site is at the base of the pentamer, where the tail of A2 emerges from the B-pentamer pore in Stx2. The final two residues of A2 pack against one of the tryptophan residues that have been shown to be crucial for the binding of Gb$_3$ at this lower affinity site (7, 32). In Stx2, the five tryptophan rings (residue 33 in each B-subunit) all have clear electron density, but they do not adopt a common conformation (Fig. 7A); whereas in the complex of a Gb$_3$ analogue with the B-pentamer of Stx1, all five tryptophan side chains have similar conformations (Fig. 7B) (6). To bind Gb$_3$ at site 3, it may be necessary for all five binding sites to be available, so that the tryptophan and the adjacent asparagine...
side chains are able to move in concert to the binding conformation. This view is supported by the structure of a mutated form of the Stx2e B-pentamer with the Gb3 analogue, in which the carbohydrate is seen to bind to sites 1 and 2, but, surprisingly, not to site 3 (8). In the crystals of this mutated Stx2e B-pentamer in complex with the Gb3 analogue, an interaction with a crystallographically related molecule causes one of the tryptophan side chains to adopt a specific conformation that is different from that in the complex of the B-pentamer of Stx1 with Gb3.

Roles for the Structural Differences in the Pathogenicity of Stx2—Four major differences between the structures of Stx and Stx2 were found in this study. First, the active site of Stx2 is accessible in the crystal structure, in contrast to the active site of Stx that is blocked by part of the polypeptide chain of A2. This greater accessibility of the Stx2 active site may contribute to the apparently greater pathogenicity of Stx2 as compared with Stx. It also means that inhibitors directed to the active site of the N-glycosidase could bind to the Stx2 holotoxin in the extracellular environment and enter the target cell in complex with the holotoxin. Within the cell, these inhibitors would prevent the toxin from shutting down protein synthesis. Second, the carboxyl terminus of the Stx2 A-subunit forms a short 2-turn a-helix after threading through the pore of the B-pentamer, in contrast to the tail of the Stx A-subunit, which in the crystal structure, in contrast to the active site of the B-pentamer, has a different conformation than found in the terminus of the Stx2 A2, could, by analogy, also be found in Stx2d-activable, and contribute to the accessibility of that peptide to elastase, which cleaves the terminal two amino acids from the A2 carboxyl terminus (34).

A greater accessibility of the Stx2 active site may contribute to the different affinities of the two B-pentamers for Gb3. Finally, the carboxyl terminus of the A1 peptide of Stx2 contributes to the different affinities of the two B-pentamers for Gb3. Third, one of the receptor binding sites in Stx2 could, by analogy, also be found in Stx2d-activable, and contribute to the accessibility of that peptide to elastase, which cleaves the terminal two amino acids from the A2 carboxyl terminus (34).

Acknowledgment—M. N. G. J. acknowledges with thanks the award of a Canada Research Chair.

REFERENCES
1. O’Loughlin, E. V., and Robins-Browne, R. M. (2001) Microbes Infection 3, 493–507
2. Shiga, K. (1898) Zentralbl. Bakteriol. Orig. 24, 913–918
3. Stein, P. E., Boodhoo, A., Tyrell, G. J., Brunton, J. L., and Read, R. J. (1992) Nature 355, 748–750
4. Siesma, T. K., Prong, S. E., Kalk, K. H., Wartna, E. S., van Zanten, B. A. M., Witholt, B., and Hol, W. G. J. (1991) Nature 351, 371–377
5. Fraser, M. E., Chernaia, M. M., Kozlov, Y. V., and James, M. N. (1994) Nat. Struct. Biol. 1, 59–64
6. Ling, H., Boodhoo, A., Hazes, B., Cummings, M. D., Armstrong, G. D., Brunton, J. L., and Read, R. J. (1998) Biochemistry 37, 1777–1788
7. Ling, H. (1999) Structural Studies of the Interactions between Shiga-like Toxins and their Carbohydrate Receptor: Ph.D. thesis, Department of Biochemistry, pp. 185, University of Alberta, Edmonton, Alberta
8. Ling, H., Pannu, N. S., Boodhoo, A., Armstrong, G. D., Clark, C. G., Brunton, J. L., and Read, R. J. (2000) Structure 8, 253–264
9. Kitow, P. I., Sadowska, J. M., Mulvey, Z., Armstrong, G. D., Ling, H., Pannu, N. S., Reed, R. J., and Bundle, D. R. (2000) Nature 403, 669–672
10. Mulvey, M. G., Marcate, P., Kitow, P. I., Sadowska, J., Bundle, D. R., and Armstrong, G. D. (2003) J. Infect. Dis. 187, 640–649
11. Osnes, S., Reising, R., and Eiklid, K. (1981) J. Biol. Chem. 256, 8723–8738
12. Reddy, M., Katzin, B., and Robertus, J. (1988) Proteins 3, 53–59
13. Melton-Celsa, A. R., and O’Brien, A. D. (2000) in Handbook of Experimental Pharmacology (Aktories, K., and Just, I., eds) pp. 355–406, Springer, Heidelberg
14. Miller, D. J., Ravikumar, K., Shen, H., Suh, J.-K., Kerwin, S. M., and Roberts, J. D. (2002) J. Med. Chem. 45, 90–98
15. Sigler, R. L., Oberg, T. G., Pyszner, T. J., Tesh, V. L., Denkers, N. D., and Taylor, F. B. (2003) Pediatr. Nephrol. 18, 92–96
16. Head, S. C., Karmali, M. A., and Lingwood, C. A. (1991) J. Biol. Chem. 266, 3617–3621
17. Tesh, V. L., Burris, J. A., Owens, J. W., Gordon, V. M., Wadolkowski, E. A., O’Brien, A. D., and Samuel, J. E. (1993) Inf. Immun. 61, 3392–3402
18. Owczarek, Z., and Minor, W. (1997) Methods Enzymol. 276, 307–326
19. Collaborative Computational Project, N. (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760–763
20. Fujimata, M., and Read, R. J. (1987) J. Appl. Crystallogr. 20, 517–521
21. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) Nucleic Acids Res. 28, 235–242
22. Brunger, A., Adams, P. D., Clore, G. M., Delano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Lages, N., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905–921
23. McRee, D. E. (1999) J. Struct. Biol. 125, 156–165
24. Jones, T. A. (1988) Methods Enzymol. 115, 157–171
25. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) J. Appl. Crystallogr. 26, 283–291
26. Hoofd, R. W. W., Vriend, G., Sander, C., and Abola, E. E. (1996) Nature 381, 272
27. Fraser, M. E., Chernaia, M. M., Kozlov, Y. V., and James, M. N. G. (1996) in Protein Toxicity and its Carbohydrate Receptors (Parkers, M. W., ed.) pp. 173–186, Springer, Heidelberg
28. Pannu, N. S., and Read, R. J. (1996) Acta Crystallogr. Sect. A 52, 659–668
29. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110–119
30. Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714–2723
31. Weston, S. A., Tucker, A. D., Thatcher, D. R., Derbysley, D. J., and Pauptit, R. A. (1994) J. Mol. Biol. 244, 410–422
32. Bast, D. J., Banerjee, L., Clark, C., Read, R. J., and Brunton, J. L. (1999) Mol. Microbiol. 32, 953–965
33. Kozlov, Y. V., Khabib, A. E., Fedchenko, V. I., and Baev, A. A. (1987) Dokl. Biochem. Biophys. 305, 740–744
VOLUME 279 (2004) PAGES 27511–27517

Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7.
Marie E. Fraser, Masao Fujinaga, Maia M. Cherney, Angela R. Melton-Celsa, Edda M. Twiddy, Alison D. O’Brien, and Michael N. G. James

PAGE 27512:

Under “Experimental Procedures,” subheading “Expression, Purification, and Crystallization of Stx2,” the name of the plasmid in the first sentence should be “pJES120.” The sentence, therefore, should read: “Stx2 was produced in E. coli DH5α using the pJES120 plasmid. . . .”

VOLUME 281 (2006) PAGES 33078 –33086

The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway.
Nancy López-Antón, Anita Rudy, Nicole Barth, M. Lienhard Schmitz, George R. Pettit, Klaus Schulze-Osthoff, Verena M. Dirsch, and Angelika M. Vollmar

Dr. Schmitz’s name did not appear in the proper order. The correct spelling and order of his name is shown above.